Nasdaq listing for France companies.
The senior US venue for growth companies. A reverse takeover reaches Nasdaq either by merging into a Nasdaq-listed shell or by uplisting from the OTC Markets once the initial listing standards are met.
For a private company in France, the Nasdaq Stock Market can be reached through a reverse takeover — the merger of the operating business into a shell company — provided the applicable listing standards are met.
- A France company can reach the Nasdaq Stock Market by merging into a listed shell, or by uplisting to it from a lower tier once the standards are met.
- Nasdaq operates three tiers — the Capital Market, the Global Market, and the Global Select Market — each with quantitative thresholds for equity or market value, public float, shareholders, and a minimum US$4.00 bid price, plus corporate-governance requirements.
- US-standard audited financials from a PCAOB-registered auditor are required, and are usually the critical-path item.
- Reverse Takeover arranges and coordinates the transaction; the regulated work is done by licensed specialists.
The route in brief
| Venue | Nasdaq — the Nasdaq Stock Market |
|---|---|
| Route | Reverse takeover into a listed shell, or uplisting from a lower tier once standards are met. |
| Standards | Nasdaq operates three tiers — the Capital Market, the Global Market, and the Global Select Market — each with quantitative thresholds for equity or market value, public float, shareholders, and a minimum US$4.00 bid price, plus corporate-governance requirements. |
| Home market | Euronext Paris · regulator AMF |
| Currency | Euro (EUR) |
| Our role | Advisory and arranger; not a broker-dealer, law firm or auditor. |
Nasdaq for France companies
France sends a distinctive profile to Nasdaq: clinical-stage biotechnology and long-horizon deep tech, where the earnings-based qualification routes are simply unavailable. That narrows the analysis. Such a company enters at the Nasdaq Capital Market on an equity or market-value route and looks at the Global Market only once a financing has lifted the float, with the tier thresholds and the US$4.00 minimum bid published through the Nasdaq Listing Center. For a French issuer the tier is a consequence of the financing, not a choice made in advance of it.
The standard that binds first is the market value of the unrestricted publicly held shares. The unrestricted qualifier is what catches French issuers: a register composed of specialist life-sciences funds, founders and BSPCE holders, much of it locked up or otherwise restricted at closing, can be large in aggregate and thin in exactly the part that counts. Round-lot holders are the second constraint, and the bid price the third for any company whose pre-merger share price is nominal.
The point discovered too late most often is tax. A clinical-stage company whose balance sheet is mostly cash can meet the passive-income or passive-asset tests and be treated as a passive foreign investment company for US federal tax purposes. That imposes real costs on US shareholders and, if a qualified electing fund election is to be available to them, requires the company to produce an annual information statement. Whether the group is in that position in any given year is a question for US tax counsel, but the diligence should begin before the merger is signed rather than at the first reporting date. On audit, French statutory accounts are certified by commissaires aux comptes under French independence rules, so confirming which candidate firms hold current registration on the PCAOB’s register of firms is a practical first step. The domestic double voting rights that attach to long-held registered shares in French companies are a separate matter to raise early, because incoming US investors will price any differential voting structure themselves.
Structuring a reverse takeover from France
A French SA or SAS group listing in the US commonly adopts a holding company acceptable to US markets. A Luxembourg, Dutch or Irish topco is often used for treaty and share-exchange efficiency. The French operating entity typically remains beneath it. France applies no exchange controls to an outbound listing. But the reorganisation engages French merger and contribution-of-securities regimes. It also engages exit-tax rules on transferring value abroad, the France–US tax treaty, and PFIC analysis for US holders. Employee-shareholding (BSPCE) and free-share plans common in French startups also need mapping into the new structure. These are decisions for French and US tax and securities counsel. Reverse Takeover arranges the transaction rather than advising on law or tax.
Considering Nasdaq for your France company?
Start an enquiry →Nasdaq listing for France companies — FAQ
Q1Can a France company list on Nasdaq via reverse takeover?
A France company can reach the Nasdaq Stock Market by merging into a shell already listed there, or by uplisting once it meets the applicable standards. Nasdaq operates three tiers — the Capital Market, the Global Market, and the Global Select Market — each with quantitative thresholds for equity or market value, public float, shareholders, and a minimum US$4.00 bid price, plus corporate-governance requirements.
Q2What are the Nasdaq listing standards?
Nasdaq operates three tiers — the Capital Market, the Global Market, and the Global Select Market — each with quantitative thresholds for equity or market value, public float, shareholders, and a minimum US$4.00 bid price, plus corporate-governance requirements. Meeting these standards, and maintaining them, is assessed with US securities counsel as part of the transaction.
Q3Is Reverse Takeover a broker-dealer?
No. Reverse Takeover is an advisory and arranger, not a registered broker-dealer, law firm or auditor. Regulated activities are performed by licensed US securities counsel, PCAOB-registered auditors, transfer agents and broker-dealers coordinated on the transaction.
Other US venues for France companies
- NYSE American listingFrance → NYSE American
- OTC Markets listingFrance → OTC Markets
- France — all routesCountry overview
This page is general, educational information about listing routes and is not investment, legal, tax, or accounting advice, nor an offer or solicitation. Regulatory details change and vary by circumstance; obtain advice from qualified US securities counsel and your home-market advisers. See our disclosures.